Header Logo

Connection

MICHAEL TAYLOR to Mutation

Back to Details
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Mutation.
MICHAEL TAYLOR
Connection Strength
2.067
Mutation
  1. p53 and Meduloblastoma. Cold Spring Harb Perspect Med. 2015 Dec 18; 6(2):a026278.
    View in: PubMed
    Score: 0.182
  2. The Amazing and Deadly Glioma Race. Cancer Cell. 2015 Sep 14; 28(3):275-7.
    View in: PubMed
    Score: 0.179
  3. ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip. Nat Genet. 2025 Jan; 57(1):88-102.
    View in: PubMed
    Score: 0.085
  4. Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene. 2004 Jun 03; 23(26):4577-83.
    View in: PubMed
    Score: 0.082
  5. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22.
    View in: PubMed
    Score: 0.064
  6. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020 04 13; 37(4):569-583.e5.
    View in: PubMed
    Score: 0.061
  7. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature. 2019 10; 574(7780):712-716.
    View in: PubMed
    Score: 0.059
  8. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Res. 2019 05 01; 79(9):2111-2123.
    View in: PubMed
    Score: 0.057
  9. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun. 2018 12 04; 6(1):134.
    View in: PubMed
    Score: 0.056
  10. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol. 2018 08; 136(2):211-226.
    View in: PubMed
    Score: 0.054
  11. Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. Dev Cell. 2018 03 26; 44(6):709-724.e6.
    View in: PubMed
    Score: 0.053
  12. Pontine Infantile Glioma Simplified. Cancer Cell. 2017 11 13; 32(5):548-549.
    View in: PubMed
    Score: 0.052
  13. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Childs Nerv Syst. 2017 Jul; 33(7):1047-1051.
    View in: PubMed
    Score: 0.050
  14. BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016 Jan; 131(1):147-50.
    View in: PubMed
    Score: 0.046
  15. Pediatric cancer genomics, a play rather than a portrait. Nat Genet. 2015 Aug; 47(8):851-2.
    View in: PubMed
    Score: 0.044
  16. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014 Dec 24; 2:174.
    View in: PubMed
    Score: 0.042
  17. Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol. 2013 Nov; 25(6):674-81.
    View in: PubMed
    Score: 0.039
  18. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29.
    View in: PubMed
    Score: 0.039
  19. Hypermutation of the inactive X chromosome is a frequent event in cancer. Cell. 2013 Oct 24; 155(3):567-81.
    View in: PubMed
    Score: 0.039
  20. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10; 31(23):2927-35.
    View in: PubMed
    Score: 0.038
  21. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32.
    View in: PubMed
    Score: 0.038
  22. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2013 Mar; 125(3):373-84.
    View in: PubMed
    Score: 0.037
  23. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16; 22(4):425-37.
    View in: PubMed
    Score: 0.037
  24. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
    View in: PubMed
    Score: 0.036
  25. Mouse models of medulloblastoma. Chin J Cancer. 2011 Jul; 30(7):442-9.
    View in: PubMed
    Score: 0.033
  26. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011 Jan 28; 331(6016):435-9.
    View in: PubMed
    Score: 0.032
  27. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010 Jul 29; 466(7306):632-6.
    View in: PubMed
    Score: 0.031
  28. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010 Mar 10; 28(8):1345-50.
    View in: PubMed
    Score: 0.030
  29. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus. 2010 Jan; 28(1):E6.
    View in: PubMed
    Score: 0.030
  30. A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science. 2022 10 07; 378(6615):68-78.
    View in: PubMed
    Score: 0.018
  31. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature. 2022 09; 609(7929):1021-1028.
    View in: PubMed
    Score: 0.018
  32. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro Oncol. 2022 01 05; 24(1):153-165.
    View in: PubMed
    Score: 0.017
  33. Spatial concordance of DNA methylation classification in diffuse glioma. Neuro Oncol. 2021 12 01; 23(12):2054-2065.
    View in: PubMed
    Score: 0.017
  34. Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discov. 2021 06; 11(6):1454-1467.
    View in: PubMed
    Score: 0.016
  35. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020 10 14; 22(10):1474-1483.
    View in: PubMed
    Score: 0.016
  36. DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. Dev Cell. 2020 08 24; 54(4):455-470.e5.
    View in: PubMed
    Score: 0.016
  37. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell. 2020 06 11; 181(6):1329-1345.e24.
    View in: PubMed
    Score: 0.015
  38. Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. J Exp Med. 2020 05 04; 217(5).
    View in: PubMed
    Score: 0.015
  39. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup. J Mol Diagn. 2020 07; 22(7):957-966.
    View in: PubMed
    Score: 0.015
  40. The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019 12; 576(7786):274-280.
    View in: PubMed
    Score: 0.015
  41. Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Rep. 2019 11 19; 29(8):2338-2354.e7.
    View in: PubMed
    Score: 0.015
  42. Recurrent noncoding U1?snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature. 2019 10; 574(7780):707-711.
    View in: PubMed
    Score: 0.015
  43. A functional genomics approach to identify pathways of drug resistance in medulloblastoma. Acta Neuropathol Commun. 2018 12 27; 6(1):146.
    View in: PubMed
    Score: 0.014
  44. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017 Nov 16; 171(5):1042-1056.e10.
    View in: PubMed
    Score: 0.013
  45. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017 08 04; 8(1):186.
    View in: PubMed
    Score: 0.013
  46. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017 Sep 01; 35(25):2934-2941.
    View in: PubMed
    Score: 0.013
  47. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 07 19; 547(7663):311-317.
    View in: PubMed
    Score: 0.013
  48. Spatial heterogeneity in medulloblastoma. Nat Genet. 2017 May; 49(5):780-788.
    View in: PubMed
    Score: 0.012
  49. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016 Dec 12; 30(6):891-908.
    View in: PubMed
    Score: 0.012
  50. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell. 2016 Mar 14; 29(3):379-393.
    View in: PubMed
    Score: 0.012
  51. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729.
    View in: PubMed
    Score: 0.011
  52. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. Pediatr Neurol. 2015 Sep; 53(3):238-242.e1.
    View in: PubMed
    Score: 0.011
  53. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22.
    View in: PubMed
    Score: 0.011
  54. Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. Clin Cancer Res. 2015 Jan 01; 21(1):184-92.
    View in: PubMed
    Score: 0.010
  55. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol. 2014 Dec; 128(6):853-62.
    View in: PubMed
    Score: 0.010
  56. Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma. Acta Neuropathol Commun. 2014 Jul 25; 2:85.
    View in: PubMed
    Score: 0.010
  57. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec; 12(12):818-34.
    View in: PubMed
    Score: 0.009
  58. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5.
    View in: PubMed
    Score: 0.009
  59. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012 May 15; 21(5):601-613.
    View in: PubMed
    Score: 0.009
  60. Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res. 2012 Feb 01; 72(3):636-44.
    View in: PubMed
    Score: 0.009
  61. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res. 2011 Apr 01; 17(7):1883-94.
    View in: PubMed
    Score: 0.008
  62. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010 Dec 10; 28(35):5188-96.
    View in: PubMed
    Score: 0.008
  63. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8.
    View in: PubMed
    Score: 0.008
  64. Retrospective family study of childhood medulloblastoma. Am J Med Genet A. 2005 May 01; 134(4):399-403.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.